Is the potent 5-HT(1A) receptor agonist, alnespirone (S-20499), affecting dopaminergic systems in the rat brain?

European Journal of Pharmacology

Volumn 350, Issue 2-3, 1998, Pages 171-180

  Dugast, Christophe ^a   Soulière, Fabienne ^a   Schmitt, Patricia ^a   Casanovas, Josep M ^b   Fattaccini, Claude Michelle ^c   Mocaër, Elizabeth ^d   Lesourd, Monique ^d   Renaud, Bernard ^a   Artigas, Francesc ^b   Hamon, Michel ^c   Chouvet, Guy ^a  

^a UNIVERSITÉ LYON 1   (France)

^b INST D INVESTIGACIONS B   (Spain)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT (5 hydroxytryptamine, serotonin) release; 5 HTP (5 hydroxytryptophan); Alnespirone (S 20499); DOPA (3,4 dihydroxyphenylalanin); DOPAC (3,4 dihydroxyphenylacetic acid); Dopamine release; HVA (homovanillic acid); Microdialysis, in vivo; Single unit recording

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALNESPIRONE; APOMORPHINE; CITALOPRAM; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; QUINPIROLE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; 5 HYDROXYTRYPTOPHAN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPA; ENZYME INHIBITOR; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SPIRO COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE CELL EXCITABILITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; BRAIN; BRAIN LEVEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; METABOLISM; MICRODIALYSIS; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

5-HYDROXYTRYPTOPHAN; ANIMALS; BRAIN; BRAIN CHEMISTRY; DIHYDROXYPHENYLALANINE; DOPA DECARBOXYLASE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SPIRO COMPOUNDS;

EID: 0345267212     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00254-4     Document Type: Article

References (54)

1. Adell A., Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn-Schmiedeberg's Arch. Pharmacol. 343:1991;237-244.
2. Ahlenius S., Hillegaart V., Wijkström A. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 339:1989;551-556.
3. Akaoka H., Charlety P., Saunier C.F., Buda M., Chouvet G. Inhibition of nigral dopamine neurons by systemic and local apomorphine: possible contribution of dendritic autoreceptors. Neuroscience. 49:1992;879-891.
4. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301 differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;353-362.
5. Arvidsson L.E., Hacksell U., Nilsson J.L.G., Hjorth S., Carlsson A., Lindberg P., Sanchez D., Wikström H. 8-Hydroxy-2-(di-n-propylamino) tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J. Med. Chem. 24:1981;921-923.
6. Arvidsson L.E., Hacksell U., Glennon R.A. Recent advances in central 5-hydroxytryptamine receptor agonists and antagonists. Prog. Drug Res. 30:1986;365-471.
7. Aulakh C.S., Wozniak K.M., Haas M., Hill J.L., Zohar J., Murphy D.L. Food intake, neuroendocrine and temperature effects of 8-OH-DPAT in the rat. Eur. J. Pharmacol. 146:1988;253-259.
8. 1A agonist, (+)S 20244 and its enantiomers (+)S 20499 and (-)S 20500. Psychopharmacology. 116:1994;73-78.
9. Benloucif S., Keegan M.J., Galloway M.P. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J. Pharmacol. Exp. Ther. 265:1993;373-377.
10. Bianchi G., Caccia S., Della Vedova F., Garattini S. The alpha-2 adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur. J. Pharmacol. 151:1988;365-371.
11. 3 receptors in rat striatum. J. Pharmacol. Exp. Ther. 251:1989;803-809.
12. 1A agonists uncouple noradrenergic somatodendritic impulse flow and terminal release. Brain Res. Bull. 27:1991;693-696.
13. Carlsson A., Davis J.N., Kehr W., Lindqvist M., Atack C.V. Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo, using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch. Pharmacol. 275:1972;153-168.
14. Casanovas J.M., Artigas F. Differential effects of ipsapirone on 5-HT release in the dorsal and median raphe neuronal pathways. J. Neurochem. 67:1996;1945-1952.
15. 1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br. J. Pharmacol. 122:1997;733-741.
16. 3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res. 543:1991;354-357.
17. Cimino M., Ponzio F., Achilli G., Vantini G., Perego C., Algeri S., Garattini S. Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem. Pharmacol. 32:1983;1069-1074.
18. Deakin J.F.W. A review of clinical efficacy of 5-HT(1A) agonists in anxiety and depression. J. Psychopharmacol. 7:1993;283-289.
19. Done C.J.G., Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT(1A) and 5-HT(2) receptors: microdialysis studies in the awake and anesthetized rat. Neuropharmacology. 33:1993;411-421.
20. Engberg G. A metabolite of buspirone increases locus coeruleus activity via alpha2-receptor blockade. J. Neural Transm. 76:1989;91-98.
21. 1B binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 332:1986;1-7.
22. Ferré S., Cortès R., Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J. Neurosci. 14:1994;4839-4846.
23. 1A receptor antagonist. Behav. Brain Res. 73:1996;337-353.
24. Gleeson S., Ahlers S.T., Mansbach R.S., Foust J.M., Barrett J.E. Behavioral studies with anxiolytic drugs: VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J. Pharmacol. Exp. Ther. 250:1989;809-817.
25. 1A partial agonists - what is their future? Drugs. 41:1991;11-18.
26. 3H -dopa in various regions of the brain J. Neurochem. 13:1966;655-669.
27. Gobbi M., Frittoli E., Mennini T. Antagonist properties of 1-(2-pyrimidinyl)-piperazine at presynaptic alpha-2 receptors in the rat brain. Eur. J. Pharmacol. 180:1990;183-186.
28. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons: 1. Identification and characterization. Neuroscience. 10:1983;301-315.
29. 1A agonists with potential anxiolytic properties. J. Pharmacol. Exp. Ther. 246:1988;745-752.
30. Hjorth S., Carlsson A., Lindberg P., Sanchez D., Wikström H., Arvidsson L.E., Hacksell U., Nilsson J.L.G. 8-hydroxy-2-(di-n-propylamino) tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. J. Neural Transm. 55:1982;169-188.
31. Hoyer D., Middlemiss D.N. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol. Sci. 10:1989;131-132.
32. Imperato A., Di Chiara G. Effects of locally applied D-1 and D-2 receptor agonists and antagonists: studies with brain dialysis. Eur. J. Pharmacol. 156:1988;385-393.
33. 1A receptors. J. Pharmacol. Exp. Ther. 264:1993;863.
34. Levy A.D., Li Q., Gustafson M., Van de Kar L.D. Neuroendocrine profile of the potential anxiolytic drug S-20499. Eur. J. Pharmacol. 274:1995;141-149.
35. Mansbach R.S., Harrod C., Hoffmann S.M., Nader M.A., Lei Z., Witkin J.M., Barrett J.E. Behavioral studies with anxiolytic drugs: V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. J. Pharmacol. Exp. Ther. 246:1988;114-120.
36. McMillen B.A., Matthews R.T., Sanghera M.K., Shepard P.D., German D.C. Dopamine receptor antagonism by the novel anti-anxiety drug buspirone. J. Neurosci. 3:1983;733-738.
37. 1A receptors: respective distributions of encoding mRNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochem. Int. 19:1991;453-465.
38. Parsons L.H., Justice J.B. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 606:1993;195-199.
39. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, Sydney.
40. Piercey M.F., Smith M.W., Lum-Ragan J.T. Excitation of noradrenergic cell firing by 5-hydroxytryptamine(1A) agonists correlates with dopamine antagonist properties. J. Pharmacol. Exp. Ther. 268:1994;1297-1303.
41. 1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 12:1992;440-453.
42. 1A agonist properties: S 20499 (+). Drug Dev. Res. 27:1992;389-402.
43. 3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area. Eur. J. Pharmacol. 214:1992;13-19.
44. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interaction in the ventral tegmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther. 271:1994;83-90.
45. Reid M.S., O'Connor W.T., Herrera-Marschitz M., Ungerstedt U. The effects of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors. Brain Res. 519:1990;255-260.
46. Sanghera M.K., McMillen B.A., German D.C. Buspirone, a non benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity. Eur. J. Pharmacol. 86:1983;107-110.
47. Sanghera M.K., Coke J.A., Williams H., McMillen B.A. Ipsapirone and 1-(2-pyrymidinyl)-piperazine increase rat locus coeruleus noradrenergic activity. Brain. Res. Bull. 24:1990;17-22.
48. Schechter L.E., Bolanos F., Gozlan H., Lanfumey L., Haj-Dahmane S., Laporte A.M., Fattaccini C.M., Hamon M. Alterations of central serotonergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J. Pharmacol. Exp. Ther. 255:1990;1335-1347.
49. 1A agonists. J. Pharmacol. Exp. Ther. 270:1994;198-208.
50. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol. 96:1989;283-290.
51. 1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists. Psychopharmacology. 108:1992;47-50.
52. Van Wijngaarden I.V., Tulp M.T.H.M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.
53. Wang R.Y. Dopaminergic neurons in the rat ventral tegmental area: I. Identification and characterization. Brain Res. Rev. 3:1981;123-140.
54. White F.J. Synaptic regulation of mesocorticolimbic dopamine neurons. Annu. Rev. Neurosci. 19:1996;405-436.